Boehringer Ingelheim has announced the approval of Striverdi Respimat olodaterol SMI for the treatment of COPD in the United Kingdom, Denmark and Iceland, noting that additional approvals in EU countries “will follow in due course.”
Boehringer Ingelheim Corporate Senior VP Medicine Klaus Dugi commented, “The improvements in lung function and quality of life seen with once-daily Striverdi Respimat are remarkable when you consider that patients in the control group were continuing with their usual care background therapies, including long- and short-acting anticholinergics, short-acting beta agonists, inhaled corticosteroids and xanthines. We are very pleased with these results and are committed to bringing Striverdi Respimat to patients worldwide who need an additional treatment option.”
The company also said that it expects to report results from a Phase 3 study of a combination of olodaterol and tiotropium early next year.
Read the BI press release.
